Loading...

CytRx

DB:CX5P
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CX5P
DB
$19M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • CytRx has significant price volatility in the past 3 months.
CX5P Share Price and Events
7 Day Returns
-13.3%
DB:CX5P
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-64.1%
DB:CX5P
-10.2%
DE Biotechs
-6%
DE Market
CX5P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CytRx (CX5P) -13.3% -23.1% -8% -64.1% -97.1% -96.3%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • CX5P underperformed the Biotechs industry which returned -10.2% over the past year.
  • CX5P underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
CX5P
Industry
5yr Volatility vs Market
Related Companies

Value

 Is CytRx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CytRx. This is due to cash flow or dividend data being unavailable. The share price is €0.495.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CytRx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CytRx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CX5P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.29
NasdaqCM:CYTR Share Price ** NasdaqCM (2019-04-18) in USD $0.56
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CytRx.

DB:CX5P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CYTR Share Price ÷ EPS (both in USD)

= 0.56 ÷ -0.29

-1.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytRx is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CytRx is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CytRx's expected growth come at a high price?
Raw Data
DB:CX5P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-12.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CytRx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CytRx's assets?
Raw Data
DB:CX5P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.61
NasdaqCM:CYTR Share Price * NasdaqCM (2019-04-18) in USD $0.56
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:CX5P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CYTR Share Price ÷ Book Value per Share (both in USD)

= 0.56 ÷ 0.61

0.92x

* Primary Listing of CytRx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CytRx is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CytRx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CytRx has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CytRx expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CytRx expected to grow at an attractive rate?
  • Unable to compare CytRx's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CytRx's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CytRx's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CX5P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CX5P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -12.6%
DB:CX5P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -149.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CX5P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CX5P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -11 1
2019-12-31 0 -8 1
DB:CX5P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -11 -9
2018-09-30 0 -15 -15
2018-06-30 0 -17 -17
2018-03-31 0 -20 -28
2017-12-31 0 -27 -30
2017-09-30 0 -29 -38
2017-06-30 0 -41 -45
2017-03-31 0 -45 -49
2016-12-31 0 -50 -51
2016-09-30 0 -54 -65
2016-06-30 0 -49 -60
2016-03-31 0 -48 -54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CytRx is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CytRx's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CX5P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from CytRx Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CX5P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.30 -0.30 -0.30 1.00
2019-12-31 -0.24 -0.24 -0.24 1.00
DB:CX5P Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.29
2018-09-30 -0.50
2018-06-30 -0.60
2018-03-31 -1.07
2017-12-31 -1.27
2017-09-30 -1.79
2017-06-30 -2.45
2017-03-31 -3.18
2016-12-31 -3.76
2016-09-30 -5.38
2016-06-30 -5.48
2016-03-31 -5.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CytRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CytRx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CytRx has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CytRx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CytRx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CytRx does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare CytRx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CytRx's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CytRx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CytRx Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CX5P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.25 -9.08 8.08 0.39
2018-09-30 0.35 -14.84 9.48 5.35
2018-06-30 0.10 -16.67 10.54 9.18
2018-03-31 0.10 -28.02 11.99 14.52
2017-12-31 0.10 -30.45 12.50 15.85
2017-09-30 0.10 -38.20 14.57 24.07
2017-06-30 0.10 -45.25 13.92 28.26
2017-03-31 0.20 -49.17 15.01 34.55
2016-12-31 0.20 -50.77 15.99 35.93
2016-09-30 0.20 -65.40 15.61 41.88
2016-06-30 0.20 -60.30 15.03 41.43
2016-03-31 0.10 -53.71 14.99 38.98
2015-12-31 0.10 -58.59 14.16 43.40
2015-09-30 0.10 -49.72 13.90 39.67
2015-06-30 0.10 -48.27 14.13 41.84
2015-03-31 0.10 -52.31 12.84 42.25
2014-12-31 0.10 -30.12 12.85 36.68
2014-09-30 0.10 -43.90 12.95 33.73
2014-06-30 0.10 -48.25 12.53 27.10
2014-03-31 0.30 -35.96 11.59 21.30
2013-12-31 0.30 -47.49 10.27 17.50
2013-09-30 0.30 -16.42 8.39 14.27
2013-06-30 0.30 -4.85 8.14 13.41
2013-03-31 0.10 -14.69 8.26 11.47
2012-12-31 0.10 -17.96 8.35 12.68
2012-09-30 0.10 -26.28 7.14 15.81
2012-06-30 0.10 -28.43 7.15 15.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CytRx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CytRx has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CytRx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CytRx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CytRx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CytRx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CytRx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CytRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CytRx has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CytRx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CytRx has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CytRx Company Filings, last reported 3 months ago.

DB:CX5P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 20.36 0.00 21.37
2018-09-30 22.35 0.00 24.67
2018-06-30 25.21 9.38 36.43
2018-03-31 21.25 10.01 35.10
2017-12-31 18.15 10.60 37.50
2017-09-30 21.47 11.05 46.00
2017-06-30 19.21 22.51 54.97
2017-03-31 14.66 24.07 48.00
2016-12-31 24.78 23.97 56.96
2016-09-30 23.60 23.76 58.88
2016-06-30 23.36 23.59 55.91
2016-03-31 33.58 23.45 68.16
2015-12-31 44.08 0.00 57.30
2015-09-30 63.52 0.00 70.80
2015-06-30 42.36 0.00 53.84
2015-03-31 51.77 0.00 65.15
2014-12-31 67.91 0.00 77.84
2014-09-30 78.19 0.00 90.03
2014-06-30 83.08 0.00 102.47
2014-03-31 98.04 0.00 112.61
2013-12-31 10.66 0.00 38.57
2013-09-30 11.14 0.00 23.04
2013-06-30 20.59 0.00 27.98
2013-03-31 23.61 0.00 32.43
2012-12-31 30.17 0.00 38.34
2012-09-30 3.76 0.00 22.45
2012-06-30 1.72 0.00 26.93
  • CytRx has no debt.
  • CytRx had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CytRx has sufficient cash runway for 2 years based on current free cash flow.
  • CytRx has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -43% each year.
X
Financial health checks
We assess CytRx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CytRx has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CytRx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CytRx dividends.
If you bought €2,000 of CytRx shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CytRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CytRx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CX5P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CX5P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CytRx has not reported any payouts.
  • Unable to verify if CytRx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CytRx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CytRx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CytRx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CytRx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CytRx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CytRx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Kriegsman
COMPENSATION $1,967,000
AGE 76
TENURE AS CEO 16.8 years
CEO Bio

Mr. Steven A. Kriegsman, also known as Steve, founded The Kriegsman Group in 1992 and serves as its President. Mr. Kriegsman also founded Kriegsman Capital Group LLC and has been its President since 1989. He has been the Chief Executive Officer at Cytrx Corporation since July 2002 and served as its President and Interim Chief Financial Officer since July 2002 and June 15, 2004 respectively. He served as the Chief Executive Officer of ANA Financial until 1989. He advised companies such as Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences Inc., Miravant Medical Technologies and Maxim Pharmaceuticals. He has more than thirty years of experience operating as a Money Manager, Financial Advisor and Merchant Banker. In 1981, he Co-founded ANA Financial Services, Inc. He founded Kriegsman Capital Group LLC. He serves as the Chairman of Kriegsman Capital Group LLC (The Kriegsman Group). He served as the Chairman of ANA Financial until 1989. He served as the Chairman of the He Board of Global Genomics since June 2000 until July 2002. He served as the Chairman at Kriegsman Capital Group LLC. He has been the Chairman of Cytrx Corporation since October 15, 2014. He served as a Director of Galena Biopharma, Inc., since 2006 until June 2016. He served as a Director at Catasys, Inc. from February 2014 to September 24, 2015. He has been a Director of Cytrx Corporation since July 2002. He served as an Independent Director at Bradley Pharmaceuticals Inc., since June 2003 until February 2008. He served as a Director of Authentidate Holding Corp., from December, 1997 to 2004. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies and Maxim Pharmaceuticals. He has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council and the Palisades-Malibu YMCA. In February 2006, he received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. He served as a Director of Hythiam Inc. until June 2009. He was formerly a Certified Public Accountant with KPMG in New York City. Mr. Kriegsman holds a B.S. degree from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute.

CEO Compensation
  • Steve's compensation has been consistent with company performance over the past year.
  • Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CytRx management team in years:

7.7
Average Tenure
60.5
Average Age
  • The average tenure for the CytRx management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Steve Kriegsman

TITLE
Chairman of the Board & CEO
COMPENSATION
$2M
AGE
76
TENURE
16.8 yrs

John Caloz

TITLE
Chief Financial Officer
COMPENSATION
$577K
AGE
66
TENURE
10.3 yrs

Felix Kratz

TITLE
Senior Vice President
COMPENSATION
$331K
AGE
55
TENURE
5.1 yrs

Eric Curtis

TITLE
President & COO
AGE
49
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the CytRx board of directors in years:

2.3
Average Tenure
69.5
Average Age
  • The average tenure for the CytRx board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Kriegsman

TITLE
Chairman of the Board & CEO
COMPENSATION
$2M
AGE
76
TENURE
4.5 yrs

Lou Ignarro

TITLE
Lead Director
COMPENSATION
$181K
AGE
76
TENURE
2.2 yrs

Earl Brien

TITLE
Director
COMPENSATION
$204K
AGE
58
TENURE
2.3 yrs

Joel Caldwell

TITLE
Director
COMPENSATION
$217K
AGE
63
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CytRx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CytRx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Details
Name: CytRx Corporation
CX5P
Exchange: DB
Founded: 1985
$16,684,058
33,637,501
Website: http://www.cytrx.com
Address: CytRx Corporation
11726 San Vicente Boulevard,
Suite 650,
Los Angeles,
California, 90049,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CYTR Common Stock Nasdaq Capital Market US USD 10. Nov 1986
DB CX5P Common Stock Deutsche Boerse AG DE EUR 10. Nov 1986
LSE 0I5R Common Stock London Stock Exchange GB USD 10. Nov 1986
Number of employees
Current staff
Staff numbers
6
CytRx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.